An Alzheimer鈥檚 disease drug was fully approved by the U.S. Food and Drug Administration this month. Leqembi, whose generic name is lecanemab, was found to slow progression of the disease by 27% by reducing certain plaques that form in the brain.
Experts say this approval could be a gateway to more advances in treatment of Alzheimer鈥檚 disease, something that affects more than six million Americans.
On Monday's "Sound of Ideas," we'll start by talking to a patient who was part of the clinical trials at the Cleveland Clinic for the drug, to learn about his and his wife鈥檚 experience dealing with the disease. And we鈥檒l talk to a local researcher who can talk about what this breakthrough means for Alzheimer鈥檚 drug research.
Also in this hour, we鈥檒l talk about the future of Cuyahoga County arts funding, after efforts to expand the tobacco tax to include vape products failed.
And, we鈥檒l hear a former comedian talk about stories from Cleveland鈥檚 stand-up scene.
Guests:
-John Domeck, Alzheimer鈥檚 disease drug trial participant
-Ann Domeck, Community educator, Alzheimer's Association & caregiver
-Mark Chance, Ph.D., Director, Center for Proteomics and Bioinformatics, Case Western Reserve University
-Jill Paulsen, Executive Director, Cuyahoga Arts & Culture
-Jeremy Johnson, President and CEO, Assembly for the Arts
-Fred Bidwell, Board Chair, Assembly for the Arts
-Mike McIntyre, Executive Editor, 精东影业
-Josh Womack, Comedian & Author, 鈥淵ou are not that funny鈥�
